University of Pennsylvania Clinical Trials Unit
Welcome,         Profile    Billing    Logout  
 6 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tebas, Pablo
NCT04060316: GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

Not yet recruiting
2
99
US
GLS-1200, Placebo, Sterile Saline
GeneOne Life Science, Inc.
Sinusitis Chronic
12/23
09/24
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

Completed
2
75
US
Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
04/24
04/24
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074

Active, not recruiting
1
15
US
Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies
Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV/AIDS, HIV-1 Infection
12/21
10/22
NCT03705169: Pharmacokinetics and Safety of SAR441236

Terminated
1
52
US
SAR441236, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics
HIV-1-infection
04/22
04/22
NCT05293249: dMAbs for Prevention of COVID-19

Active, not recruiting
1
61
US
dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
Pablo Tebas, The Wistar Institute, AstraZeneca, Inovio Pharmaceuticals
Healthy Volunteers
09/25
09/25
Frank, Ian
NCT05854381: To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

Active, not recruiting
1
95
US, RoW
VIR-1388, Placebo
Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network
HIV I Infection
11/25
11/27
Hansen-Flaschen, Susan L
No trials found
Hollen, Eileen
No trials found

Download Options